Drug Trial Radar · NCT06230224
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
216
Actual
Start
Feb 15, 2024
Primary completion
May 29, 2028
Study completion May 29, 2028
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Jan 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as 'refractory') or has returned (also known as 'relapsed'). The aim of the study is to see how safe, tolerable and effective the study drug is when given alone. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug versus Standard of Care (SOC) * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * Comparing the impact from the study drug versus SOC on quality-of-life and ability to complete routine daily activities
Conditions
- B-Cell Non-Hodgkin Lymphoma (B-NHL)
Interventions
OdronextamabDrug
Administered by intravenous (IV) infusion
IfosfamideDrug
Administered by IV infusion, as part of the ICE ± R salvage therapy
CarboplatinDrug
Administered by IV infusion, as part of the ICE ± R salvage therapy
EtoposideDrug
Administered by IV infusion, as part of the ICE ± R salvage therapy
RituximabDrug
Administered by IV infusion, as part of the ICE ± R, or DHAP ± R, or GDP ± R salvage therapy.
DexamethasoneDrug
Administered by IV, or orally (PO) as part of the DHAP ± R, or GDP ± R salvage therapy.
CisplatinDrug
Administered by IV infusion, as part of the DHAP ± R or GDP +/-R salvage therapy.
CytarabineDrug
Administered by IV infusion, as part of the DHAP ± R salvage therapy.
GemcitabineDrug
Administered by IV infusion, as part of the GDP ± R salvage therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-Free Survival (EFS) as assessed by independent central review (ICR)Time frame: Assessed up to 3 years
Locations
81 sites in 14 countries. Site status is shown where the registry gives one.
Sanatorio Allende
Córdoba, Argentina
Hospital Privado Universitario de Cordoba
Córdoba, Argentina
Hospital Aleman
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Hospital Britanico de Buenos Aires
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Instituto Alexander Fleming
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Fundaleu - Fundacion Para Combatir La Leucemia
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Hospital Italiano de Buenos Aires
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Hospital Italiano de La Plata
La Plata, Buenos Aires, Argentina
Hospital Alta Complejidad El Cruce
San Juan Bautista, Buenos Aires, Argentina
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Olivia Newton John Cancer Wellness & Research Centre
Heidelberg, Victoria, Australia
Instituto Nacional de Cancer Jose Alencar Gomes da Silva
Rio de Janeiro, Brazil
Hospital Sirio Libanes
São Paulo, Brazil
A Beneficencia Portuguesa de Sao Paulo, Oncology House
São Paulo, Brazil
Instituto D'Or De Pesquisa e Ensino
São Paulo, Brazil
Hospital das Clinicas, Faculty of Medicine, University of Sao Paulo
São Paulo, Brazil
Casa de Saude Santa Marcelina
São Paulo, Brazil
Hospital Santa Izabel - Santa Casa de Misericordia da Bahia
Salvador, Estado de Bahia, Brazil
Hospital Sao Rafael
Salvador, Estado de Bahia, Brazil
Ensino e Terapia de Inovacao Clinica Amo (Etica)
Salvador, Estado de Bahia, Brazil
Hospital Sirio Libanes Brasilia
Brasília, Federal District, Brazil
Uopeccan Hospital do Cancer de Cascavel
Cascavel, Paraná, Brazil
Hospital Erasto Gaertner
Curitiba, Paraná, Brazil
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Centro Gaucho Integrado
Porto Alegre, Rio Grande do Sul, Brazil
Amaral Carvalho Hospital
Jaú, São Paulo, Brazil
Fundacion Arturo Lopez Perez
Santiago, Santiago Metropolitan, Chile
Clinica Alemana de Santiago
Santiago, Santiago Metropolitan, Chile
Hospital Pablo Tobon Uribe
Medellín, Antioquia, Colombia
Clinica Imbanaco
Cali, Valle del Cauca Department, Colombia
Semmelweis University
Budapest, Hungary
University of Pecs
Pécs, Baranya, Hungary
Debreceni Egyetem
Debrecen, Hajdú-Bihar, Hungary
Hospital Sultanah Aminah Jhor Bahru
Johor Bahru, Johor, Malaysia
University Malaya Medical Centre
Kuala Lumpur, Kuala Lumpur, Malaysia
Hospital Queen Elizabeth
Kota Kinabalu, Sabah, Malaysia
Hospital Ampang
Kuala Lumpur, Selangor, Malaysia
Subang Jaya Medical Center
Subang Jaya, Selangor, Malaysia
Coltea Clinical Hospital
Bucharest, Bucharest, Romania
Ion Chiricuta Oncology Institute
Cluj-Napoca, Cluj, Romania
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.